NCT02888743 2026-03-19
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
19 trialsNCT04034927 2026-03-18
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT03057106 2026-03-03
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT02519348 2026-02-17
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT03965468 2026-02-09
CHESS
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT04395079 2026-02-09
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03937830 2026-02-05
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03158064 2026-01-28
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03410615 2026-01-14
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04238637 2025-12-05
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04817826 2025-06-10
INFINITY
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT03601455 2025-04-13
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05000710 2024-12-05
CORAL-Lung
Sheba Medical Center
Phase 2 Active not recruiting
NCT05027425 2024-11-22
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Active not recruiting
NCT03959293 2024-07-08
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT03046862 2024-04-19
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT04169841 2024-02-13
GUIDE2REPAIR
Centre Georges Francois Leclerc
Phase 2 Active not recruiting